Compass-logo-RGB-outlines.png
Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference
May 23, 2022 08:00 ET | Compass Therapeutics
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
May 09, 2022 08:00 ET | Compass Therapeutics
The FDA cleared the investigational new drug application for CTX-009 (DLL4 X VEGF-A bispecific) in January allowing the Company to expand the ongoing Phase 2 study in patients with biliary tract...
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers
May 04, 2022 07:00 ET | Compass Therapeutics
CTX-009 Demonstrated a 42% Overall Response Rate (ORR) Based on 10 Partial Responses (PRs) in 24 Enrolled Patients CTX-009 Continues to be Well Tolerated, Consistent with the Phase 1 Studies ...
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 21, 2022 08:00 ET | Compass Therapeutics
Ended 2021 with $144.5 million in cash and cash equivalentsCTX-009 (DLL4 X VEGF-A bispecific antibody) Global Phase 2 study in patients with advanced biliary tract cancers (BTC) is progressing well;...
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.
March 03, 2022 07:30 ET | Helsinn Healthcare S.A.
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S. Helsinn gains an exclusive...
Compass-logo-RGB-outlines.png
Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)
January 20, 2022 08:30 ET | Compass Therapeutics
BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
logo.jpg
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada
December 20, 2021 08:03 ET | Helsinn Healthcare S.A.
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada Lugano, Switzerland, and Mississauga, Ontario, 20 December 2021 – Helsinn Group...
PCI logo from eps file.jpg
PCI Biotech: Presentation of fimaChem for bile duct cancer at IPA masterclass series
November 08, 2021 05:15 ET | PCI Biotech Holding ASA
Oslo (Norway), 8 November 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the coordinating principal investigator for the RELEASE trial, Prof. Dr. Jörg...
PCI logo from eps file.jpg
PCI Biotech receives Orphan Drug Designation in South Korea for fimaporfin in the treatment of bile duct cancer
May 28, 2021 08:51 ET | PCI Biotech Holding ASA
Oslo, 28 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that the Ministry of Food and Drug Safety (MFDS) in South Korea has granted Orphan Drug...
FBI LOGO.jpg
Biliary Tumor Market to Gain Traction in the Coming Years; Advancements in NuCana’s Breakthrough Pipeline Drug Will Boost the Market, says Fortune Business Insights
June 19, 2019 07:45 ET | Fortune Business Insights
Pune, June 19, 2019 (GLOBE NEWSWIRE) -- The global Biliary Tumor Market is likely to derive growth from increasing usage approvals in the forthcoming years. According to an upcoming report by...